A5026751554- Myeloproliferative Neoplasms: Diagnosis and Treatment
- BRCA gene mutations in cancer
- Kruppel-like factors research
- Ocular Oncology and Treatments
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Nutrition, Genetics, and Disease
- Genomics and Rare Diseases
- Chronic Myeloid Leukemia Treatments
- Circular RNAs in diseases
- Eosinophilic Disorders and Syndromes
- Biochemical and Structural Characterization
- Epigenetics and DNA Methylation
- Geography and Environmental Studies
- T-cell and Retrovirus Studies
- Global Cancer Incidence and Screening
- Glioma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Protein Hydrolysis and Bioactive Peptides
- Cancer survivorship and care
- Genetic factors in colorectal cancer
- Acute Myeloid Leukemia Research
- Women's cancer prevention and management
Universidade Federal de Juiz de Fora
2012-2024
Mendelics
2023
Fundação Oswaldo Cruz
2016-2022
Antimicrobial peptides (AMPs) are compounds that act in a wide range of physiological defensive mechanisms developed to counteract bacteria, fungi, parasites and viruses. These molecules have become increasingly important as consequence remarkable microorganism resistance common antibiotics. This report shows Escherichia coli expressing the recombinant antimicrobial peptide Pg-AMP1 previously isolated from Psidium guajava seeds. The deduced open reading frame consists 168 bp long plus...
Myeloproliferative neoplasms are caused by a clonal proliferation of hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated the World Health Organization classification system 2011, myeloproliferative include polycythemia vera, essential thrombocythemia primary myelofibrosis subgroup called breakpoint cluster region-Abelson fusion oncogene-negative neoplasms. According to regarding diagnosis criteria for neoplasms, presence JAK2 V617F mutation is...
Patients with cancer often undergo multiple extended treatments that decrease their quality of life. However, the life women breast after they treatment remains underexplored in Brazil. Therefore, this study determined sociodemographic, behavioral, and clinical factors related to post-treatment cancer.
Abstract Objective The study aimed to characterize the clinical, histological, and immunohistochemical profile of women with invasive breast cancer, according risk for Hereditary Predisposition Breast Ovarian Cancer Syndrome in a Brazilian population. Methods This is retrospective performed from hospital-based cohort 522 women, diagnosed cancer treated at an oncology referral center Southeast region Brazil, between 2014 2016. Results Among 430 who composed population, 127 (29.5%) were...
This literature review aims to inform and assist physicians other health professionals in managing all information related hereditary breast cancer, which is constant rapid growth, allowing for improvement patient care assistance. In addition, we seek better identify patients are eligible the clinical criteria of association with risk based on international recommendations highlighting main high moderate penetrance genes that make up multigenic panels germline investigation as well...
10631 Background: Brazil has a highly admixed population with significant Southern European, African and Native American genetic ancestries. Approximately 75% of the two or more continental Therefore, breast cancer polygenic risk scores (PRS) developed in predominantly European populations requires validation Brazilian population. Compared genotyping arrays whole genome sequencing, affordable scalable exome sequencing (WES) allows both rare common variants targeted regions imputation not...
Introduction: Malignant breast cancer is the second most common type of among women in world, leaving behind nonmelanoma skin cancer. The aim this study was to identify germline variants BRCA1 and BRCA2 genes diagnosed with southeastern region Brazil. Methods: This part a retrospective study, performed from hospital-based cohort, consisting 522 women. 92 patients were excluded because they had carcinoma situ did not present clinical information, totaling 430 patients. Of these, we molecular...